OptimizeRx Corporation provided preliminary financial guidance for the third quarter ended September 30, 2023. For the third quarter, the company expects revenue between $15.2 million and $15.5 million. Net loss is expected to be in the range of $4.1 million to $4.0 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
10.84 USD | -0.69% | +1.69% | -24.53% |
29/04 | OptimizeRx Corporation Provides Earnings Guidance for the First Quarter of 2024 | CI |
16/04 | Earnings Flash (OPRX) OPTIMIZERX CORPORATION Posts Q4 Revenue $28.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.53% | 198M | |
+26.36% | 439B | |
+25.33% | 264B | |
+8.75% | 141B | |
+6.93% | 93.43B | |
+25.85% | 90.41B | |
+56.80% | 59.45B | |
+16.00% | 47.5B | |
+3.86% | 37.3B | |
+20.84% | 36.11B |
- Stock Market
- Equities
- OPRX Stock
- News OptimizeRx Corporation
- OptimizeRx Corporation Provides Preliminary Financial Guidance for the Third Quarter Ended September 30, 2023